Korean J Physiol Pharmacol.  2001 Feb;5(1):79-86.

Differentiation induction of dendritic cell phenotypes from human leukemic cell lines

• Lee DH
• Park JS
• Eo WK
• Kim WM
• Kang K

Abstract

Recent clinical studies have shown that a high proportion of patients with acute promyelocytic leukemia (APL) achieve complete remission after treatment with all-trans retinoic acid (ATRA). However, most patients who receive continuous treatment with ATRA relapse and develop ATRA-resistant leukemia. Dendritic cells (DCs) are important antigen-presenting cells in the development of antileukemic T-cell responses. In this study, we investigated the strategies to overcome ATRA resistance of APL cells by inducing the differentiation of DCs from human leukemic cell lines for the developtment of adoptive immunotherapy. CD83 was used as a mature DC marker in this study and the expression of CD83 mRNA was determined by RT-PCR method. The promyelocytic leukemic cell line HL-60, B lymphoblast cell lines RPMI 7666 and NC-37 could be induced to dendritic cells in vitro. Treatment of HL-60 with phorbol 12-myristate 13-acetate (PMA) resulted in the expression of myeloid-related DC phenotypes, while treatment of RPMI 7666 with fms-like tyrosine kinase 3 ligand (Flt3-ligand, FL) and treatment of NC-37 with PMA and FL led to the expression of lymphoid-related DC phenotypes. In conclusion, myeloid-related DC phenotypes and lymphoid-related DC phenotypes could be generated from HL-60, NC-37 and RPMI 7666 cell lines, respectively. These DC phenotypes can potentially be used to generate antileukemic T cells in vitro for adoptive immunotherapy.

MeSH Terms

Antigen-Presenting Cells
Cell Line*
Dendritic Cells*
fms-Like Tyrosine Kinase 3
Humans*
Immunotherapy, Adoptive
Leukemia
Leukemia, Promyelocytic, Acute
Phenotype*
Recurrence
RNA, Messenger
T-Lymphocytes
Tretinoin
RNA, Messenger
Tretinoin
fms-Like Tyrosine Kinase 3